Maxim Group reissued their buy rating on shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) in a report issued on Thursday morning. The brokerage currently has a $3.00 target price on the biotechnology company’s stock.

Actinium Pharmaceuticals (NYSEMKT:ATNM) traded up 0.56% during mid-day trading on Thursday, reaching $0.72. The company had a trading volume of 975,473 shares. Actinium Pharmaceuticals has a 52 week low of $0.54 and a 52 week high of $1.72. The stock’s 50-day moving average price is $0.61 and its 200 day moving average price is $1.08. The firm’s market capitalization is $57.61 million.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/06/actinium-pharmaceuticals-inc-atnm-receives-buy-rating-from-maxim-group.html.

A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. Virtu KCG Holdings LLC lifted its holdings in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) by 957.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 442,964 shares of the biotechnology company’s stock after purchasing an additional 401,084 shares during the period. Virtu KCG Holdings LLC owned about 0.76% of Actinium Pharmaceuticals worth $540,000 as of its most recent filing with the Securities & Exchange Commission.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Stock Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.